Future Directions and Targeted Therapies in Bladder Cancer

Hematology/Oncology Clinics of North America

Volumn 29, Issue 2, 2015, Pages 361-376

  Sonpavde, Guru ^a   Jones, Benjamin S ^a   Bellmunt, Joaquim ^b   Choueiri, Toni K ^b   Sternberg, Cora N ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Biologic agents; Systemic therapy; Therapeutic targets; Urothelial carcinoma

Indexed keywords

ALT 801; ANTINEOPLASTIC AGENT; APATORSEN; BEVACIZUMAB; BUPARLISIB; CABAZITAXEL; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERIBULIN; EVEROLIMUS; GEMCITABINE; ICRUCUMAB; IPILIMUMAB; LAPATINIB; MPDL 3280A; PACLITAXEL; PAZOPANIB; PEMBROLIZUMAB; PEMETREXED; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEDOTIN; VINFLUNINE;

ADVANCED CANCER; BLADDER CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; METASTASIS POTENTIAL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; THROMBOEMBOLISM; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CANCER STAGING; CLINICAL TRIAL (TOPIC); MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84933672294     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.10.008     Document Type: Review

References (98)

1. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. JClin Oncol 2005, 23(21):4602-4608.
2. Sonpavde G., Sternberg C.N., Rosenberg J.E., et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010, 11(9):861-870.
3. Bellmunt J., Theodore C., Demkov T., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. JClin Oncol 2009, 27(27):4454-4461.
4. Bellmunt J., von der Maase H., Mead G.M., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. JClin Oncol 2012, 30(10):1107-1113.
5. Galsky M.D., Hahn N.M., Rosenberg J., et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. JClin Oncol 2011, 29(17):2432-2438.
6. Sonpavde G., Watson D., Tourtellott M., et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer 2012, 10(1):1-5.
7. De Santis M., Bellmunt J., Mead G., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. JClin Oncol 2012, 30(2):191-199.
8. Sonpavde G., Galsky M.D., Latini D., et al. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin Genitourin Cancer 2014, 12(2):71-73.
9. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507(7492):315-322.
10. Damrauer J.S., Hoadley K.A., Chism D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 2014, 111(8):3110-3115.
11. Choi W., Porten S., Kim S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25(2):152-165.
12. Sjodahl G., Lauss M., Lovgren K., et al. Amolecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012, 18(12):3377-3386.
13. Iyer G., Al-Ahmadie H., Schultz N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. JClin Oncol 2013, 31(25):3133-3140.
14. Volkmer J.P., Sahoo D., Chin R.K., et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA 2012, 109(6):2078-2083.
15. Chan K.S., Espinosa I., Chao M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009, 106(33):14016-14021.
16. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366(26):2443-2454.
17. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. NEngl J Med 2013, 369(2):134-144.
18. Powles T., Vogelzang N., Fine G.D., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in patients with metastatic urothelial bladder cancer. JClin Oncol 2014, 32(5 Suppl). [abstract: 5011].
19. Bellmunt J., Petrylak D.P., Powles T., et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer. ESMO congress 2014, abstract 8080.
20. Plimack E.R., Gupta S., Bellmunt J., et al. A phase 1b study of pembrolizumab in patients with advanced urothelial tract cancer. ESMO Congress 2014, abstract LBA23.
21. Liakou C.I., Kamat A., Tang D.N., et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008, 105(39):14987-14992.
22. Fishman M.N., Thompson J.A., Pennock G.K., et al. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res 2011, 17(24):7765-7775.
23. Milowsky M.I., Dittrich C., Martinez I.D., et al. Final results of a multicenter, open-label phase II trial of dovitinib in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. JClin Oncol 2013, 31(Suppl 6). [abstract: 255].
24. Guagnano V., Kauffmann A., Wohrle S., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012, 2(12):1118-1133.
25. Sequist LV, Cassier P, Varga A, etal. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. American Association for Cancer Research Annual Meeting 2014. San Diego, April 5-9, 2014; Abstract: CT326.
26. Bahleda R., Dienstmann R., Adamo B., et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. JClin Oncol 2014, 32(5 Suppl). [abstract: 2501].
27. Sjodahl G., Lauss M., Gudjonsson S., et al. Asystematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011, 6(4):e18583.
28. Wagle N., Grabiner B.C., Van Allen E.M., et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014, 4(5):546-553.
29. Iyer G., Hanrahan A.J., Milowsky M.I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338(6104):221.
30. Milowsky M.I., Iyer G., Regazzi A.M., et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013, 112(4):462-470.
31. Buckley M.T., Yoon J., Yee H., et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth invitro and invivo. JTransl Med 2007, 5:49.
32. Cheung E.M., Quinn D.I., Tsao-Wei D.D., et al. Phase II study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy-California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. JClin Oncol 2008, 26(15 Suppl):16058.
33. Hahn N.M., Bonney P.L., Dhawan D., et al. Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. JUrol 2012, 187(1):302-309.
34. Clozel T., Yang S., Elstrom R.L., et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 2013, 3(9):1002-1019.
35. Miyake H., Hara I., Yamanaka K., et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999, 39(2):123-129.
36. Bernardini S., Fauconnet S., Chabannes E., et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. JUrol 2001, 166(4):1275-1279.
37. Nakanishi R., Oka N., Nakatsuji H., et al. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 2009, 83(1):98-106.
38. Bochner B.H., Cote R.J., Weidner N., et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. JNatl Cancer Inst 1995, 87(21):1603-1612.
39. Hahn N.M., Stadler W.M., Zon R.T., et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. JClin Oncol 2011, 29(12):1525-1530.
40. Balar A.V., Apolo A.B., Ostrovnaya I., et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. JClin Oncol 2013, 31(6):724-730.
41. Chaudhary U.B., Golshayan A.R., Brisendine A., et al. Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder. JClin Oncol 2011, 29(Suppl 7). [abstract: 276].
42. Siefker-Radtke A.O., Kamet A.M., Corn P.G., et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high risk urothelial cancer: results from a phase II trial at the M. D. Anderson Cancer Center. JClin Oncol 2012, 30(Suppl 5). [abstract: 261].
43. Bellmunt J., Gonzalez-Larriba J.L., Prior C., et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011, 22(12):2646-2653.
44. Gallagher D.J., Milowsky M.I., Gerst S.R., et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. JClin Oncol 2010, 28(8):1373-1379.
45. Grivas P.D., Daignault S., Tagawa S.T., et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 2014, 120(5):692-701.
46. Galsky M.D., Hahn N.M., Powles T., et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013, 11(2):175-181.
47. Garcia J.A., Stephenson A.J., Ireland J., et al. Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder. JClin Oncol 2011, 29(Suppl 7). [abstract: 262].
48. Necchi A., Mariani L., Zaffaroni N., et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012, 13(8):810-816.
49. Pili R., Qin R., Flynn P.J., et al. Aphase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 2013, 11(4):477-483.
50. Srinivas S., Narayanan S., Harshman L.C., et al. Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer. JClin Oncol 2014, 32(Suppl 4). [abstract: 299].
51. Gerullis H., Eimer C., Ecke T.H., et al. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs 2013, 24(4):422-425.
52. Choueiri T.K., Ross R.W., Jacobus S., et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. JClin Oncol 2012, 30(5):507-512.
53. Sridhar S.S., Winquist E., Eisen A., et al. Aphase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 2011, 29(5):1045-1049.
54. Dreicer R., Li H., Stein M., et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009, 115(18):4090-4095.
55. Krege S., Rexer H., vom Dorp F., et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int 2014, 113(3):429-436.
56. Mehnert J.M., Mortazavi A., Stein M.N., et al. Aphase II trial of gemcitabine, carboplatin, and sorafenib in patients with transitional cell carcinoma: preliminary safety and outcome. JClin Oncol 2011, 29(Suppl 7). [abstract: 278].
57. Apolo A.B., Parnus H.L., Madan R.A., et al. Aphase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. JClin Oncol 2013, 31(Suppl). [abstract: 4577].
58. Apolo A.B., Tomita Y., Lee M.J., et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. JClin Oncol 2014, 32(5 Suppl). [abstract: 4501].
59. Twardowski P., Stadler W.M., Frankel P., et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010, 76(4):923-926.
60. Mita A.C., Takimoto C.H., Mita M., et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010, 16(11):3044-3056.
61. Jian W., Levitt J.M., Lerner S.P., et al. The angiopoietin-tie2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Res 2014, 34(7):3377-3382.
62. Jian W., Levitt J.M., Lerner S.P., et al. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res 2014, 34(7):3383-3389.
63. Jinesh G.G., Lee E.K., Tran J., et al. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy invivo. Urol Oncol 2013, 31(8):1676-1682.
64. Lonn U., Lonn S., Friberg S., et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995, 1(10):1189-1194.
65. Sriplakich S., Jahnson S., Karlsson M.G. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer?. BJU Int 1999, 83(4):498-503.
66. Chaux A., Cohen J.S., Schultz L., et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 2012, 43(10):1590-1595.
67. Hussain M., Daignault S., Agarwal N., et al. Arandomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 2014, 120(17):2684-2693.
68. Wong Y.N., Litwin S., Vaughn D., et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. JClin Oncol 2012, 30(28):3545-3551.
69. Petrylak D.P., Tangen C.M., Van Veldhuizen P.J., et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010, 105(3):317-321.
70. Philips G.K., Halabi S., Sanford B.L., et al. Aphase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009, 20(6):1074-1079.
71. Hussain M.H., MacVicar G.R., Petrylak D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. JClin Oncol 2007, 25(16):2218-2224.
72. Oudard S., Culine S., Vieillefond A., et al. Multicenter randomized phase 2 trial of gemcitabine-platinum with or without trastuzumab (T) in advanced/metastatic urothelial carcinoma (A/MUC) with HER2 overexpression. ESMO Congress conference, Vienna, Austria, September 2012, [abstract: 1111].
73. Galsky M.D., Von Hoff D.D., Neubauer M., et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012, 30(2):695-701.
74. Wulfing C., Machiels J.P., Richel D.J., et al. Asingle-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009, 115(13):2881-2890.
75. Bajorin D.F., Gomella L.G., Sharma P., et al. Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence. JClin Oncol 2014, 32(5 Suppl). [abstract: 4541].
76. Kamada M., So A., Muramaki M., et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007, 6(1):299-308.
77. Ko Y.J., Canil C.M., Mukherjee S.D., et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013, 14(8):769-776.
78. Grivas P.D., Hussain M., Hafez K., et al. Aphase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology 2013, 82(1):111-117.
79. Hoffman-Censits J.H., Vaughn D.J., Lin J., et al. Aphase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy. JClin Oncol 2014, 32(Suppl). [abstract: e15519].
80. Quinn D.I., Aparicio A., Tsao-Wei D.D., et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: a California Cancer Consortium-led NCI/CTEP-sponsored trial. JClin Oncol 2010, 28(15 Suppl). [abstract: 4539].
81. Quinn DI, Twardowski PW, Wei YE, etal. Phase II study of eribulin in platinum-treated, tubulin naive advanced urothelial cancer (UC) - A California Cancer Consortium trial (NCI/CTEP 7435). ECCO. Conference, Amsterdam, The Netherlands, September 2013, [abstract: 2704].
82. Galsky M.D., Mironov S., Iasonos A., et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007, 25(3):265-270.
83. Sweeney C.J., Roth B.J., Kabbinavar F.F., et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. JClin Oncol 2006, 24(21):3451-3457.
84. Benjamin D.J., Bamburg R.M., Chaim J., et al. Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer. JClin Oncol 2014, 32(Suppl 4). [abstract: 322].
85. Zhou N., Singh K., Mir M.C., et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells invitro and invivo. Clin Cancer Res 2013, 19(7):1717-1728.
86. Sonpavde G., Goldman B.H., Speights V.O., et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009, 115(18):4104-4109.
87. Paz-Ares L.G., Solsona E., Esteban E., et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. JClin Oncol 2010, 28(18 Suppl). LBA 4518.
88. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. NEngl J Med 2003, 349(9):859-866.
89. Sternberg C.N., Skoneczna I.A., Kerst J.M., et al. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. JClin Oncol 2014, 32(5 Suppl). [abstract: 4500].
90. Sonpavde G., Khan M.M., Lerner S.P., et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. JUrol 2011, 185(2):456-461.
91. Apolo A.B., Ostrovnaya I., Halabi S., et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. JNatl Cancer Inst 2013, 105(7):499-503.
92. Galsky M.D., Moshier E., Krege S., et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 2013, 119(16):3012-3019.
93. Galsky M.D., Krege S., Lin C.C., et al. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer 2013, 119(16):3020-3026.
94. Sonpavde G., Galsky M.D., Bellmunt J. Anew approach to second-line therapy for urothelial cancer?. Lancet Oncol 2013, 14(8):682-684.
95. Sonpavde G., Pond G.R., Fougeray R., et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 2013, 63(4):717-723.
96. Bellmunt J., Choueiri T.K., Fougeray R., et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. JClin Oncol 2010, 28(11):1850-1855.
97. Pond G.R., Agarwal N., Bellmunt J., et al. Anomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int 2014, 113(5b):E137-E143.
98. Agarwal N., Bellmunt J., Maughan B.L., et al. Six-month progression-free survival asthe primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer 2014, 12(2):130-137.